Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Update

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 800 shares, a decrease of 57.9% from the September 15th total of 1,900 shares. Based on an average trading volume of 8,400 shares, the short-interest ratio is currently 0.1 days.

Santen Pharmaceutical Stock Performance

OTCMKTS SNPHY remained flat at $11.76 on Friday. The company’s stock had a trading volume of 202 shares, compared to its average volume of 6,826. The stock’s 50 day simple moving average is $12.22 and its two-hundred day simple moving average is $10.94. Santen Pharmaceutical has a 1-year low of $8.31 and a 1-year high of $13.00.

About Santen Pharmaceutical

(Get Free Report)

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.

Further Reading

• Five stocks we like better than Santen Pharmaceutical
• Canadian Penny Stocks: Can They Make You Rich?
• Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
• What is Forex and How Does it Work?
• Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
• What is the Euro STOXX 50 Index?
• 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside